<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A patient with central <z:mp ids='MP_0008912'>nervous</z:mp> system involvement of <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease was refractory to conventional immunosuppressive therapy and showed secondary failure of the anti-TNF agent infliximab </plain></SENT>
<SENT sid="1" pm="."><plain>This presented as a progressive <z:mp ids='MP_0000746'>weakness</z:mp> of the legs and reduction in walking distance </plain></SENT>
<SENT sid="2" pm="."><plain>The cerebrospinal fluid showed signs of <z:mp ids='MP_0001845'>inflammation</z:mp> including a vastly elevated IL-6 concentration </plain></SENT>
<SENT sid="3" pm="."><plain>Given this result, the anti-IL-6 receptor antibody tocilizumab was administered and a good improvement of inflammatory parameters and a satisfactory increase of the walking distance were achieved </plain></SENT>
</text></document>